Ting-Ting Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ting-Ting Zhao has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Hao Xu
Department of Medical Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, China
2 shared publications - Hui-Mian Xu
Department of Surgical Oncology, First Hospital of China Medical University, Shenyang, Liaoning Province, China
2 shared publications - Xing-Yu Liu
Department of Surgical Oncology, First Hospital of China Medical University, Shenyang, Liaoning Province, China
2 shared publications - Yingying Xu
Department of Breast Surgery, The First Hospital of China Medical University, Shenyang, Liaoning Province, China.
2 shared publications - Yongxi Song
Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors (China Medical University), Ministry of Education, 155 North Nanjing Street, Heping District, Shenyang, 110001, China
2 shared publications - Zhenning Wang
Department of Surgical Oncology and General Surgery, The First Affiliated Hospital of China Medical University, Shenyang, China
2 shared publications
Latest Publications
- Open Access
- 1 January 2025
- Published by Maximum Academic Press in Gastrointestinal Tumors
- Vol. 12 (1)
Exploring the applications of gastric organoids in disease modeling and personalized medicine
Organoid systems are capable of forming three-dimensional self-organizing structures that closely recapitulate the cellular composition and physiological functions of native gastric tissue. Since their introduction, gastric organoid technology has rapidly advanced and become a powerful tool for studying gastric development, disease mechanisms, and therapeutic responses. This review summarizes key developments in the field, with a focus on five major areas of application: gastric developmental biology, modeling of Helicobacter pylori infection, research on gastric cancer and drug resistance, assessment of personalized therapy, and regenerative medicine. Distinct from previous reviews, this article systematically traces the evolution of gastric organoid technology and provides an in-depth analysis of current limitations in microenvironment reconstruction, standardized culture, immune co-culture modeling, and clinical translation. In addition, it discusses emerging strategies and integrated technologies aimed at overcoming these challenges, offering perspectives to advance organoid systems from basic research toward clinical application.
- 1 January 2025
- Published by Maximum Academic Press in Gastrointestinal Tumors
- Vol. 12 (1)
Open AccessExploring the applications of gastric organoids in disease modeling and personalized medicine
Organoid systems are capable of forming three-dimensional self-organizing structures that closely recapitulate the cellular composition and physiological functions of native gastric tissue. Since their introduction, gastric organoid technology has rapidly advanced and become a powerful tool for studying gastric development, disease mechanisms, and therapeutic responses. This review summarizes key developments in the field, with a focus on five major areas of application: gastric developmental biology, modeling of Helicobacter pylori infection, research on gastric cancer and drug resistance, assessment of personalized therapy, and regenerative medicine. Distinct from previous reviews, this article systematically traces the evolution of gastric organoid technology and provides an in-depth analysis of current limitations in microenvironment reconstruction, standardized culture, immune co-culture modeling, and clinical translation. In addition, it discusses emerging strategies and integrated technologies aimed at overcoming these challenges, offering perspectives to advance organoid systems from basic research toward clinical application.
- Open Access
- 13 February 2019
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 1-9
The role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small cell lung cancer: a systematic review and meta-analysis
The brain is a common site for metastasis in non-small-cell lung cancer (NSCLC). This study was designed to evaluate the relationship between the mutational of the epidermal growth factor receptor (EGFR) and overall survival (OS) in NSCLC patients with brain metastases. Searches were performed in PubMed, EmBase, and the Cochrane Library to identify studies evaluating the association of EGFR mutation with OS in NSCLC patients through September 2017. 4373 NSCLC patients with brain metastases in 18 studies were involved. Mutated EGFR associated with significantly improved OS compared with wild type. Subgroup analyses suggested that this relationship persisted in studies conducted in Eastern, with retrospective design, with sample size ≥500, mean age of patients ≥65.0 years, percentage male < 50.0%, percentage of patients receiving tyrosine kinase inhibitor ≥30.0%. Finally, although significant publication bias was observed using the Egger test, the results were not changed after adjustment using the trim and fill method. This meta-analysis suggests that EGFR mutation is an important predictive factor linked to improved OS for NSCLC patients with brain metastases. It can serve as a useful index in the prognostic assessment of NSCLC patients with brain metastases.
- 13 February 2019
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 1-9
Open AccessThe role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small cell lung cancer: a systematic review and meta-analysis
The brain is a common site for metastasis in non-small-cell lung cancer (NSCLC). This study was designed to evaluate the relationship between the mutational of the epidermal growth factor receptor (EGFR) and overall survival (OS) in NSCLC patients with brain metastases. Searches were performed in PubMed, EmBase, and the Cochrane Library to identify studies evaluating the association of EGFR mutation with OS in NSCLC patients through September 2017. 4373 NSCLC patients with brain metastases in 18 studies were involved. Mutated EGFR associated with significantly improved OS compared with wild type. Subgroup analyses suggested that this relationship persisted in studies conducted in Eastern, with retrospective design, with sample size ≥500, mean age of patients ≥65.0 years, percentage male < 50.0%, percentage of patients receiving tyrosine kinase inhibitor ≥30.0%. Finally, although significant publication bias was observed using the Egger test, the results were not changed after adjustment using the trim and fill method. This meta-analysis suggests that EGFR mutation is an important predictive factor linked to improved OS for NSCLC patients with brain metastases. It can serve as a useful index in the prognostic assessment of NSCLC patients with brain metastases.
- Open Access
- 31 January 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 118
Effect of neoadjuvant chemotherapy in patients with gastric cancer: a PRISMA-compliant systematic review and meta-analysis
Neoadjuvant chemotherapy (NAC) is extensively used in the treatment of patients with gastric cancer (GC), particularly in high risk, advanced gastric cancer. Previous trials testing the efficacy of NAC have reported inconsistent results. This study compares the combined use of NAC and surgery with surgery alone for GC by using a meta-analytic approach. We performed an electronic search of PubMed, EmBase, and the Cochrane Library to identify randomized controlled trials (RCTs) on NAC published before Oct 2015. The primary outcome of the studies was data on survival rates for patients with GC. The summary results were pooled using the random-effects model. We included 12 prospective RCTs reporting data on 1538 GC patients. Patients who received NAC were associated with significant improvement of OS (P = 0.001) and PFS (P < 0.001). Furthermore, NAC therapy significantly increased the incidence of 1-year survival rate (SR) (P = 0.020), 3-year SR (P = 0.011), and 4-year SR (P = 0.001). Similarly, NAC therapy was associated with a lower incidence of 1-year (P < 0.001), 2-year (P < 0.001), 3-year (P < 0.001), 4-year (P = 0.001), and 5-year recurrence rate (P = 0.002). Conversely, patients who received NAC also experienced a significantly increased risk of lymphocytopenia (P = 0.003), and hemoglobinopathy (P = 0.021). The findings of this study suggested that NAC is associated with significant improvement in the outcomes of survival and disease progression for GC patients while also increasing some toxicity.
- 31 January 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 118
Open AccessEffect of neoadjuvant chemotherapy in patients with gastric cancer: a PRISMA-compliant systematic review and meta-analysis
Neoadjuvant chemotherapy (NAC) is extensively used in the treatment of patients with gastric cancer (GC), particularly in high risk, advanced gastric cancer. Previous trials testing the efficacy of NAC have reported inconsistent results. This study compares the combined use of NAC and surgery with surgery alone for GC by using a meta-analytic approach. We performed an electronic search of PubMed, EmBase, and the Cochrane Library to identify randomized controlled trials (RCTs) on NAC published before Oct 2015. The primary outcome of the studies was data on survival rates for patients with GC. The summary results were pooled using the random-effects model. We included 12 prospective RCTs reporting data on 1538 GC patients. Patients who received NAC were associated with significant improvement of OS (P = 0.001) and PFS (P < 0.001). Furthermore, NAC therapy significantly increased the incidence of 1-year survival rate (SR) (P = 0.020), 3-year SR (P = 0.011), and 4-year SR (P = 0.001). Similarly, NAC therapy was associated with a lower incidence of 1-year (P < 0.001), 2-year (P < 0.001), 3-year (P < 0.001), 4-year (P = 0.001), and 5-year recurrence rate (P = 0.002). Conversely, patients who received NAC also experienced a significantly increased risk of lymphocytopenia (P = 0.003), and hemoglobinopathy (P = 0.021). The findings of this study suggested that NAC is associated with significant improvement in the outcomes of survival and disease progression for GC patients while also increasing some toxicity.